Injected capital in Tianjing Hengjia, expand into clinical medical field
Injected capital in Shanghai Youlong Biotech Co., Ltd, further expand product/service portfolio of the Group, further extend client/business coverage
Fully acquired NBS Biologicals Ltd.,in the UK with the aim of expanding into the European market
Disposal of all of Sangon Biotech’s equity interest in PrimeGene to an Independent Third Party
On the main board of the Hongkong Stock Exchange
Establishment of Guangzhou branch
Acquisition of the land use rights for Songjiang District, Shanghai, to expand our facilities
Sangon Biotech changed from a limited company to a stock limited company
Acquisition of equity interest in Shanghai PrimeGene Bio-Tech Co., Ltd.
Integration of the overseas businesses by acquiring all of the assets and businesses in the provision of life sciences products and services of BIO Basic Inc. and Bio Basic USA Inc.
Acquisition of properties in Beijing, Wuhan, Canada and New York for manufacturing, warehousing and sales office purposes
Incorporation of Bio Basic Canada Inc., a wholly-owned subsidiary in Canada
Incorporation of Bio Basic, Inc., a wholly-owned subsidiary in the US
Establishment of Beijing and Wuhan branches
Incorporation of BBI US
Integration of the domestic businesses of the Group by way of Sangon Biotech acquiring all of the assets and business related to the production and operation of life sciences products and services of SSBETS
Completed construction of headquarters and manufacturing facilities at Songjiang District, SH
Acquisition of the land use rights at 698 Xiangmin Road, Chedun Town, Songjiang District, Shanghai for R&D and production
Incorporation of BBI Canada and commencement of sales and distribution of life sciences research products and services to overseas customers
Incorporation of Sangon Biotech, the Group’s operating subsidiary in the PRC
Incorporation of SSBETS and commence business at Songjiang District, Shanghai